You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
  1. CORPORATE - 07-01-2016

    Human rabies Ig meets primary endpoint in U.S. pivotal phase 2/3 clinical trial

    Strategic agreement between Kedrion and Kamada for its clinical development and marketing

    read more 
  2. CORPORATE - 12-10-2015

    Kedrion supports Fondazione Paracelso's activities in Afghanistan

    Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries

    read more 
  3. CORPORATE - 29-09-2015

    Kedrion Notes 2019 Tender Offer results

    Kedrion has accepted for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000

    read more 
  4. CORPORATE - 21-09-2015

    Cash Tender Offer for Notes due 24 April 2019

    Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019

    read more 

Pages

For more information please contact: pressoffice@kedrion.com